A Cheat Sheet to New Groups that Use “340B” in Their Names

Cheat Sheet
340B Report Publisher and CEO Ted Slafsky's latest column for Verity Solutions is a cheat sheet for the growing number of groups using "340B" in their names.

With so many advocacy groups using the term “340B” in their name these days, it’s easy to confuse one with another. Ted Slafsky’s latest column for Verity Solutions is a guide to the menagerie.

Slafsky, publisher and CEO

Read More »

AHF: Addressing Syphilis Disparities in Franklin County, OH

Aids Healthcare Foundation logo

SPONSORED CONTENT

In 1999, the Centers for Disease Control and Prevention (CDC) launched the National Campaign to Eliminate Syphilis from the United States. The CDC updated its ambitious plan in 2006 and aimed to reduce rates of primary and secondary syphilis to less than 2.2 cases per 100,000 population, congenital syphilis

Read More »

RxStrategies’ Launches “340B Insider Podcast” Series

In the episode “340B Insights: The Current State of the 340B Program,” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Ted Slafsky, Publisher and CEO of the 340B Report to share information on what’s important to Covered Entities and pharmacy professionals who manage a 340B Program and provide the best care to those they serve.

Read More »

In Wake of 340B Contract Pharmacy Restrictions, Biosimilars Deserve Consideration

SPONSORED CONTENT

Recent surveys confirm what those of you reading this know painfully well: Hospital and clinic pharmacies are struggling from the restrictions drug manufacturers are placing on 340B pricing at contract pharmacy sites. As the 340B world awaits another batch of court rulings and hopes for the best, the exclusions are harming patients’ ability

Read More »

Our Top 10 Breaking News Stories of 2022

Top 10 graphic image
A judge’s decision in February to vacate the federal government’s letter telling AstraZeneca its 340B contract pharmacy policy is illegal was our top breaking news story of 2022.

A judge’s decision in February to vacate the federal government’s letter telling AstraZeneca its 340B contract pharmacy policy is illegal was our top breaking news story of 2022.

Number two on the list (based on how often a

Read More »

For 2-3 Years, CMS Could Pay 340B Hospitals More for Pricey New Alzheimer’s Drug Than Current Norm

A box and bottle of prescription drug Aduhelm
MedPAC says that for two or three years CMS likely would pay 340B hospitals more for the expensive new Alzheimer's drug Aduhelm than it normally would for a Part B drug.

Medicare likely would pay 340B hospitals 106% of the average sales price (ASP) for Aduhelm—Biogen’s high-cost biologic drug for early-stage Alzheimer’s disease—for the first two or three years it is on the market, not the ASP minus 22.5%

Read More »

340B Covered Entities: Are You Ready for the Changes to Gilead’s Advancing Access Program?

SPONSORED CONTENT

This strategy could save the 340B proceeds at your organization

Today, underinsured or uninsured patients who are undergoing treatment with a Gilead HIV treatment or preventative medication may be eligible to receive those medications at no cost through Gilead’s Advancing Access program. Under this program, covered entities are able to receive full 340B proceeds from these dispenses and can use these funds

Read More »

U.S. Supreme Court Schedules Oral Arguments on 340B Reimbursement Case

The Supreme Court’s decision to hear the case over Medicare-related 340B cuts to hospitals surprised many observers. Oral arguments are scheduled for Nov. 30, with a decision not likely until the spring.

The U.S. Supreme Court has announced the cases it will take up this fall and 340B will be on the plate. The court recently posted its hearings schedule for the months of October through December and will

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer